NO20013966L - Kombinasjoner for behandling av sykdommer som involverer angiogenese - Google Patents

Kombinasjoner for behandling av sykdommer som involverer angiogenese

Info

Publication number: NO20013966L
Authority: NO; Norway
Prior art keywords: combinations; treatment; diseases involving; involving angiogenesis; formation
Prior art date: 1999-02-16

Application number

NO20013966A

Other languages

English (en)

Norwegian (no)

Other versions

NO20013966D0 (no

Inventor

Peter David Davis

Original Assignee

Angiogene Pharm Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-16

Filing date

2001-08-15

Publication date

2001-10-15

2001-08-15 Application filed by Angiogene Pharm Ltd filed Critical Angiogene Pharm Ltd

2001-08-15 Publication of NO20013966D0 publication Critical patent/NO20013966D0/no

2001-10-15 Publication of NO20013966L publication Critical patent/NO20013966L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Electrotherapy Devices (AREA)
Ultra Sonic Daignosis Equipment (AREA)

NO20013966A 1999-02-16 2001-08-15 Kombinasjoner for behandling av sykdommer som involverer angiogenese NO20013966L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9903404.3A GB9903404D0 (en)	1999-02-16	1999-02-16	Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
PCT/GB2000/000511 WO2000048591A1 (en)	1999-02-16	2000-02-15	Combinations for the treatment of diseases involving angiogenesis

Publications (2)

Publication Number	Publication Date
NO20013966D0 NO20013966D0 (no)	2001-08-15
NO20013966L true NO20013966L (no)	2001-10-15

Family

ID=10847791

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20013966A NO20013966L (no)	1999-02-16	2001-08-15	Kombinasjoner for behandling av sykdommer som involverer angiogenese

Country Status (21)

Country	Link
US (2)	US7087627B1 (da)
EP (1)	EP1161235B1 (da)
JP (1)	JP4708569B2 (da)
KR (2)	KR20070034642A (da)
CN (1)	CN1344159B (da)
AT (1)	ATE288264T1 (da)
AU (1)	AU775242B2 (da)
BR (1)	BR0008254A (da)
CA (1)	CA2362281C (da)
DE (1)	DE60017878T2 (da)
DK (1)	DK1161235T3 (da)
ES (1)	ES2237407T3 (da)
GB (1)	GB9903404D0 (da)
HK (1)	HK1040919B (da)
IL (2)	IL144847A0 (da)
MX (1)	MXPA01008245A (da)
NO (1)	NO20013966L (da)
NZ (1)	NZ513429A (da)
PT (1)	PT1161235E (da)
WO (1)	WO2000048591A1 (da)
ZA (1)	ZA200106688B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001247459A (ja)	2000-03-03	2001-09-11	Oakland Uniservices Ltd	癌の組み合わせ療法
EE200200565A (et)	2000-03-31	2004-06-15	Angiogene Pharmaceuticals Ltd.	Vaskulaarse kahjustava toimega kombinatsioonravi
EP1311262A4 (en)	2000-07-28	2005-06-01	Cancer Rec Tech Ltd	COMBINED TREATMENT AGAINST CANCER
US20050153939A1 (en)	2003-09-10	2005-07-14	Bristol-Myers Squibb Company	Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
US6670344B2 (en)	2000-09-14	2003-12-30	Bristol-Myers Squibb Company	Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
HUP0302629A3 (en) *	2000-10-27	2005-05-30	Aventis Pharma Sa	Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
JP2004523517A (ja) *	2000-12-22	2004-08-05	ブリストル−マイヤーズスクイブカンパニー	腫瘍増殖および転移を調節するための方法
US20020183266A1 (en) *	2001-03-15	2002-12-05	Aventis Pharma, S.A.	Combination comprising combretastatin and anticancer agents
AU2008202468B2 (en) *	2001-07-13	2011-08-11	Oxigene, Inc.	Compositions and Methods of Administering Tubulin Binding Agents for the Treatment of Ocular Diseases
WO2003006002A1 (en) *	2001-07-13	2003-01-23	Oxigene, Inc.	Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
ATE311228T1 (de) *	2001-08-30	2005-12-15	Cancer Rec Tech Ltd	Antikrebs-kombinationen aus dmxaa und paclitaxel oder docetaxel
GB0121285D0 (en)	2001-09-03	2001-10-24	Cancer Res Ventures Ltd	Anti-cancer combinations
GB2386836B (en)	2002-03-22	2006-07-26	Cancer Res Ventures Ltd	Anti-cancer combinations
GB2394658A (en)	2002-11-01	2004-05-05	Cancer Rec Tech Ltd	Oral anti-cancer composition
CA2669138A1 (en) *	2006-11-09	2008-12-04	University Of Maryland, Baltimore	Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
WO2008100591A2 (en) *	2007-02-14	2008-08-21	The General Hospital Corporation	Modulation of nitric oxide signaling to normalize tumor vasculature
PT2219451E (pt)	2007-11-21	2015-02-09	Oxigene Inc	Processo para o tratamento de neoplasmas hematopoiéticos
US9353150B2 (en)	2012-12-04	2016-05-31	Massachusetts Institute Of Technology	Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014144715A1 (en)	2013-03-15	2014-09-18	Memorial Sloan-Kettering Cancer Center	Hsp90-targeted cardiac imaging and therapy
US11419934B2 (en)	2015-08-18	2022-08-23	Oncotelic Therapeutics, Inc.	Use of VDAS to enhance immunomodulating therapies against tumors
WO2017197045A1 (en)	2016-05-11	2017-11-16	Movassaghi Mohammad	Convergent and enantioselective total synthesis of communesin analogs
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en)	2019-06-05	2022-12-27	Massachusetts Institute Of Technology	Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL107771A0 (en)	1992-11-27	1994-02-27	Wellcome Found	Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation
US5554638A (en) *	1993-05-24	1996-09-10	Duke University	Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5424447A (en) *	1993-07-07	1995-06-13	The Medical College Of Wisconsin Research Foundation, Inc.	Heme binding compounds and use thereof
GB9320484D0 (en)	1993-10-05	1993-11-24	Wellcome Found	Pharmaceutical combinations
WO1996018617A1 (en) *	1994-12-12	1996-06-20	Merck & Co., Inc.	Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
CA2238029A1 (en)	1996-03-05	1997-09-12	Medinox, Inc.	Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
US5916910A (en) *	1997-06-04	1999-06-29	Medinox, Inc.	Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore

1999
- 1999-02-16 GB GBGB9903404.3A patent/GB9903404D0/en not_active Ceased
2000
- 2000-02-15 BR BR0008254-6A patent/BR0008254A/pt not_active Application Discontinuation
- 2000-02-15 DE DE60017878T patent/DE60017878T2/de not_active Expired - Fee Related
- 2000-02-15 KR KR1020077004923A patent/KR20070034642A/ko not_active Application Discontinuation
- 2000-02-15 JP JP2000599383A patent/JP4708569B2/ja not_active Expired - Fee Related
- 2000-02-15 CA CA002362281A patent/CA2362281C/en not_active Expired - Fee Related
- 2000-02-15 CN CN008050961A patent/CN1344159B/zh not_active Expired - Fee Related
- 2000-02-15 IL IL14484700A patent/IL144847A0/xx active IP Right Grant
- 2000-02-15 EP EP00903832A patent/EP1161235B1/en not_active Expired - Lifetime
- 2000-02-15 US US09/890,989 patent/US7087627B1/en not_active Expired - Fee Related
- 2000-02-15 DK DK00903832T patent/DK1161235T3/da active
- 2000-02-15 ES ES00903832T patent/ES2237407T3/es not_active Expired - Lifetime
- 2000-02-15 NZ NZ513429A patent/NZ513429A/en not_active IP Right Cessation
- 2000-02-15 AT AT00903832T patent/ATE288264T1/de not_active IP Right Cessation
- 2000-02-15 AU AU25590/00A patent/AU775242B2/en not_active Ceased
- 2000-02-15 KR KR1020017010121A patent/KR20010102038A/ko active IP Right Grant
- 2000-02-15 WO PCT/GB2000/000511 patent/WO2000048591A1/en not_active Application Discontinuation
- 2000-02-15 PT PT00903832T patent/PT1161235E/pt unknown
- 2000-02-15 MX MXPA01008245A patent/MXPA01008245A/es active IP Right Grant
2001
- 2001-08-09 IL IL144847A patent/IL144847A/en not_active IP Right Cessation
- 2001-08-14 ZA ZA200106688A patent/ZA200106688B/en unknown
- 2001-08-15 NO NO20013966A patent/NO20013966L/no unknown
2002
- 2002-04-08 HK HK02102577.5A patent/HK1040919B/zh not_active IP Right Cessation
2006
- 2006-05-01 US US11/416,283 patent/US20060198846A1/en not_active Abandoned

Also Published As

Publication number	Publication date
GB9903404D0 (en)	1999-04-07
MXPA01008245A (es)	2002-10-23
HK1040919A1 (en)	2002-06-28
WO2000048591A1 (en)	2000-08-24
IL144847A0 (en)	2002-06-30
AU2559000A (en)	2000-09-04
DE60017878D1 (de)	2005-03-10
PT1161235E (pt)	2005-05-31
CA2362281C (en)	2008-11-18
US20060198846A1 (en)	2006-09-07
CN1344159B (zh)	2011-09-28
EP1161235A1 (en)	2001-12-12
NZ513429A (en)	2003-10-31
KR20070034642A (ko)	2007-03-28
DE60017878T2 (de)	2006-01-26
JP4708569B2 (ja)	2011-06-22
HK1040919B (zh)	2005-05-13
ES2237407T3 (es)	2005-08-01
NO20013966D0 (no)	2001-08-15
EP1161235B1 (en)	2005-02-02
BR0008254A (pt)	2001-11-06
US7087627B1 (en)	2006-08-08
CA2362281A1 (en)	2000-08-24
JP2002537251A (ja)	2002-11-05
DK1161235T3 (da)	2005-05-09
ATE288264T1 (de)	2005-02-15
CN1344159A (zh)	2002-04-10
IL144847A (en)	2006-10-31
ZA200106688B (en)	2002-08-14
KR20010102038A (ko)	2001-11-15
AU775242B2 (en)	2004-07-22

Publication	Publication Date	Title
NO20013966D0 (no)	2001-08-15	Kombinasjoner for behandling av sykdommer som involverer angiogenese
TR199801151T2 (xx)	1998-08-21	Trombin inhibit�r� �n ila�lar.
ATE332129T1 (de)	2006-07-15	Behandlung der akne mit lipoxygenase inhibitoren
RS50031B (sr)	2008-11-28	Triciklični inhibitori poli(adp-riboza)polimeraza
NZ592550A (en)	2012-12-21	Compostion comprising antibody capable of binding to p40 subunit of IL-12
ATE339406T1 (de)	2006-10-15	Chinazoline verbindungen als heilmittel
NO954427D0 (no)	1995-11-06	Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
ES2421948T3 (es)	2013-09-06	Compuestos y composiciones para suministrar agentes activos
AU2001266575A1 (en)	2002-01-08	Chemical compounds
DK0900233T3 (da)	2001-01-22	Steroid-nitrit- og -nitratesterderivater, der kan anvendes som antiinflammatoriske lægemidler
IT1285770B1 (it)	1998-06-18	Composti corticoidei
AU2002213421A1 (en)	2002-04-15	Condensed pyridoindole derivatives
WO2002070469A3 (en)	2004-03-04	Selective pde3b inhibitors and use of the same in therapy
WO2000040583A3 (de)	2000-09-21	Imidazo[4,5-c]-pyridin-4-on-derivate
MXPA01011606A (es)	2003-09-10	Terapia anti-inflamatoria para infeccion mediada por inflamacion.
WO2001056555A3 (en)	2002-08-08	Use of cox-2 inhibitors for the treatment of constipation
DK0866870T3 (da)	2003-06-23	Vævsfaktor-Kunitz-domæne-fusionsproteiner som inhibitorer for faktor Vlla
AR020563A1 (es)	2002-05-15	Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
AU2002213419A1 (en)	2002-04-15	Condensed pyridoindole derivatives
AU2001263278A1 (en)	2002-01-08	Cyclic gmp-specific phosphodiesterase inhibitors
HRP20050439B1 (en)	2007-11-30	New use of dextran sulfate
NO911459D0 (no)	1991-04-15	Anvendelse av metallion-komplekser som belegginhibitorer.
DE60121048D1 (de)	2006-08-03	PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
AU2001296699A1 (en)	2002-05-21	Condensed pyrazindione derivatives as pde inhibitors
DE60122559D1 (de)	2006-10-05	Indolderivate als pde5-inhibitoren